Medtronic, FDA approvals and acquisitions are continuously happening... From arrhythmia to neurointervention, the expansion pace is accelerating

Medtronic ($MDT) has achieved significant clinical and regulatory milestones in recent months in the fields of arrhythmia treatment, cardiovascular diagnostics, neurointervention, and surgical robotics, accelerating business expansion. With new product approvals, acquisitions, and subsidiary listings, its “product portfolio upgrade” strategy is becoming increasingly clear.

Expansion of Cardiac Electrophysiology Business

The most notable area is the cardiac electrophysiology business. On April 25, Medtronic announced clinical and regulatory milestones for the Affera system and Sphere-9, Sphere-360 catheters. Mid-term data for ventricular tachycardia (VT) patients show a 65.5% non-recurrence rate at six months. The U.S. Food and Drug Administration (FDA) has designated the Sphere-9 catheter as an “innovative medical device” and approved its Investigational Device Exemption (IDE) for key clinical trials in the U.S. Sphere-360 achieved 100% lesion durability in the left common pulmonary vein subgroup analysis and received CE marking in Europe this January. Clinical trials in the U.S. are also currently enrolling patients.

Additionally, the “Conquer-AF” study evaluating Sphere-9’s efficacy in atrial fibrillation (AFib) patients undergoing repeat ablation has completed its first patient enrollment. Given the market characteristics of high arrhythmia recurrence and the need for repeat procedures, these data may serve as an opportunity for Medtronic to expand influence in the high-value electrophysiology device market.

Acquisition of Cardiovascular Diagnostics and AI Solutions

In cardiovascular diagnostics, the acquisition of CathWorks is seen as a key move. On April 20, Medtronic announced the completion of its acquisition of CathWorks for a total of $585 million (approximately 8.641 trillion KRW). Additional performance-based earnouts have not been disclosed. Through this acquisition, Medtronic gains the AI-based coronary physiology assessment system “FFRangio.” This device analyzes functional stenosis using only angiographic images, without drugs or pressure wires, and is available in the U.S., Europe, and Japan.

Clinical evidence has also been obtained. In the randomized “ALL-RISE” trial with over 1,900 participants, FFRangio demonstrated non-inferiority to traditional wire-based FFR in the one-year major adverse cardiovascular events (MACE) endpoint. Medtronic views this acquisition as having no significant impact on EPS for fiscal year 2027 but expects neutral or beneficial profit contributions thereafter. This is interpreted as a strategic move to incorporate AI diagnostic solutions into the existing hardware-centric product portfolio, thereby gaining control over hospital decision-making processes.

Strengthening Neurointervention and Surgical Platforms

The neurointervention field continues to expand. Medtronic agreed to acquire Scientia Vascular for $550 million (about 812.6 billion KRW). The goal is to combine its guidewire and catheter technologies with Medtronic’s neurovascular product portfolio to improve stroke treatment accessibility. Approximately 310 employees will be included in this deal, which is expected to close in the first half of FY2027. The company anticipates that, although there may be slight pressure on adjusted EPS in the first year, the acquisition will have a positive impact on performance afterward.

The surgical platform division has also been strengthened. On March 27, Medtronic received FDA approval for its “Stealth Axis” system used in cranial and ENT surgeries. The system integrates surgical planning, navigation, robotic technology, and AI-based nerve fiber tracking within the AiBLE ecosystem. This expands its application scope following the spine indication approval in February this year. The system can work in conjunction with GE Healthcare’s intraoperative ultrasound solutions and is designed as a scalable platform connecting multiple departments.

Cardiac Rhythm Management and Business Restructuring

A new milestone has been reached in cardiac rhythm management devices. Medtronic’s OmniaSecure defibrillator lead received FDA approval on March 23, adding indications for left bundle branch area (LBB) pacing in cardiac conduction system (CSP). This is the first approval of such an indication for a defibrillator lead. The lead features a 4.7 French lumenless design and can be used in patients aged 12 and above. In the LEADR LBBAP trial, implant success was 100%, and the rate of device-related serious adverse events at three months was 2.1%. The product began commercial launch in the U.S. in January this year.

In terms of business restructuring, the listing of the Medtronic MiniMed diabetes management subsidiary marks a significant turning point. MiniMed started trading on the Nasdaq Global Select Market on March 6. The company issued 28 million shares at $20 each, with an over-allotment option for an additional 4.2 million shares. Post-IPO, Medtronic expects to hold about 90.03% of shares; if the over-allotment is fully exercised, the stake will be 88.70%. The company states this IPO is the second-largest in medical device industry history. This aligns with Medtronic’s strategy to reallocate capital to core businesses amid increasing geopolitical uncertainties.

Shareholder Returns and Investor Communication

The shareholder return outlook remains steady. Medtronic announced a quarterly dividend of $0.71 per share for FY2026 Q4. At an exchange rate of 1,477.50 KRW per USD, this is approximately 1,049 KRW per share. The ex-dividend date is March 27, with a payout date of April 17. The company has achieved 48 consecutive years of annual dividend increases, demonstrating its stability as a “dividend aristocrat” in the S&P 500.

Investor communication is also ongoing. CFO Thierry Piéton will participate in major investor conferences on March 10-11 to discuss business status. Subsequently, Medtronic will release FY2026 Q4 and full-year results on June 3. The earnings summary will be released at 5:45 a.m. Central Time, with a live video webcast starting at 6:45 a.m.

Transition to an Integrated Platform Enterprise

Overall, recent developments indicate that Medtronic is accelerating its transformation from a pure medical device manufacturer into an integrated platform company combining AI-based diagnostics, precision surgery, robotics, and data connectivity. The FDA approvals, clinical achievements, and strategic acquisitions support this direction. Whether these new businesses will translate into actual sales growth and improved profitability in future earnings reports remains a key focus.

TP AI Disclaimer: This article is summarized based on the TokenPost.ai language model. It may omit main content or differ from actual facts.